About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7364 record(s)
Req # A-2024-001127
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-108016-770, Deputy Ministerial Meeting with the Food and Biologics Laboratories.Organization: Health Canada
January 2025
Req # A-2024-001128
Adverse Drug Reaction (ADR). Report number: 001105313.Organization: Health Canada
January 2025
Req # A-2024-001129
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07277786, E2B_07277588, E2B_07305771, E2B_07188397, E2B_07280528, E2B_06647559, E2B_06733896, E2B_06067651, E2B_07288711, E2B_07035040.Organization: Health Canada
January 2025
Req # A-2024-001132
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-108304-762, Deputy Ministerial Attendance at Event: Public Policy Forum's Fall Lecture 2024: Canada’s Relationship with the United States.Organization: Health Canada
January 2025
Req # A-2024-001143
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07260682, E2B_07302196, E2B_07289202, E2B_07277761, E2B_07232658, E2B_07302815, E2B_07277745, E2B_07374906, E2B_07372301, E2B_07357402.Organization: Health Canada
January 2025
Req # A-2024-001145
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07320794, 001083465, E2B_07371958, E2B_07337706, E2B_07374805, E2B_07378579, E2B_07386026, E2B_07372301, E2B_07391385, 001114870.Organization: Health Canada
January 2025
Req # A-2024-001146
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07383501, E2B_07357402, E2B_07415375, E2B_07414754, E2B_07405718, E2B_07405746. ADRs for Leuprolide. Report numbers: E2B_07286169, E2B_07286169.Organization: Health Canada
January 2025
Req # A-2024-001153
Adverse Drug Reactions (ADRs). Report numbers: E2B_05862742, E2B_06186716, 1031530, E2B_05969683, E2B_05969586, E2B_06151402, E2B_06131046, E2B_06090780, E2B_06083598, E2B_03470780.Organization: Health Canada
January 2025
Req # A-2024-001159
Adverse Drug Reactions (ADRs). Report numbers: E2B_07451809, E2B_07489089.Organization: Health Canada
January 2025
Req # A-2024-001165
Adverse Drug Reactions (ADRs). Report numbers: 001088091, 001087623, E2B_07102726, E2B_07087654, E2B_07054910.Organization: Health Canada
January 2025